Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis
暂无分享,去创建一个
Douglas A Lauffenburger | Suzanne Gaudet | Peter K Sorger | D. Lauffenburger | P. Sorger | S. Gaudet | B. Aldridge | Bree B Aldridge | Peter K. Sorger | Bree B. Aldridge
[1] P. Scheurich,et al. Segregation of APO‐1/Fas antigen‐ and tumor necrosis factor receptor‐mediated apoptosis , 1994, European journal of immunology.
[2] O. Wolkenhauer,et al. Thresholds in transient dynamics of signal transduction pathways. , 2010, Journal of theoretical biology.
[3] D. Vaux,et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Lauffenburger,et al. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. , 2008, Molecular cell.
[5] M. Peter,et al. Differences between CD95 type I and II cells detected with the CD95 ligand. , 1999, Cell death and differentiation.
[6] Guy S. Salvesen,et al. X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.
[7] H. Walczak,et al. Is TRAIL the holy grail of cancer therapy? , 2009, Apoptosis.
[8] R A Knight,et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes , 2009, Cell Death and Differentiation.
[9] Yigong Shi,et al. Molecular mechanisms of caspase regulation during apoptosis , 2004, Nature Reviews Molecular Cell Biology.
[10] K. Kinzler,et al. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.
[11] T. Wilson,et al. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells , 2009, Oncogene.
[12] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[13] Yili Yang,et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. , 2000, Science.
[14] C. Ceccarini,et al. Some paradoxical effects of inhibitors of protein synthesis on protein turnover in cultured human cells , 1976, In Vitro.
[15] D. Lauffenburger,et al. Modeling a Snap-Action, Variable-Delay Switch Controlling Extrinsic Cell Death , 2008, PLoS biology.
[16] F. Allgöwer,et al. Bistability Analyses of a Caspase Activation Model for Receptor-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[17] M. Peter,et al. Differences between CD95 type I and type II cells detected with the CD95 ligand [1] , 1999 .
[18] Ingo Schmitz,et al. Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells* , 1999, The Journal of Biological Chemistry.
[19] Maike A. Laussmann,et al. The Caspase-8 Dimerization/Dissociation Balance Is a Highly Potent Regulator of Caspase-8, -3, -6 Signaling* , 2010, The Journal of Biological Chemistry.
[20] Alicia Algeciras-Schimnich,et al. Two CD95 tumor classes with different sensitivities to antitumor drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Penrose,et al. THE CORRELATION BETWEEN RELATIVES ON THE SUPPOSITION OF MENDELIAN INHERITANCE , 2022 .
[22] Ingo Schmitz,et al. The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.
[23] G. Salvesen,et al. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.
[24] G. Savich,et al. Smac/DIABLO release from the mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation , 2010 .
[25] Wafik S El-Deiry,et al. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.
[26] G. Vinnicombe,et al. Fundamental limits on the suppression of molecular fluctuations , 2010, Nature.
[27] D. Green,et al. Inducible Dimerization and Inducible Cleavage Reveal a Requirement for Both Processes in Caspase-8 Activation* , 2010, The Journal of Biological Chemistry.
[28] K. Jaqaman,et al. Robust single particle tracking in live cell time-lapse sequences , 2008, Nature Methods.
[29] G M Cohen,et al. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis , 2002, Cell Death and Differentiation.
[30] Malabika Sarker,et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. , 2004, The Journal of cell biology.
[31] Stephanie Birkey Reffey,et al. Characterization of XIAP-Deficient Mice , 2001, Molecular and Cellular Biology.
[32] M. Peter,et al. The CD95 type I/type II model. , 2003, Seminars in immunology.
[33] Peter Schow,et al. Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.
[34] Jochen H M Prehn,et al. Systems analysis of effector caspase activation and its control by X‐linked inhibitor of apoptosis protein , 2006, The EMBO journal.
[35] C. Hallas,et al. The role of receptor internalization in CD95 signaling , 2006, The EMBO journal.
[36] J. Tavaré,et al. Rapid caspase‐3 activation during apoptosis revealed using fluorescence‐resonance energy transfer , 2000, EMBO reports.
[37] M. Butterworth,et al. Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein* , 2002, The Journal of Biological Chemistry.
[38] J. D. Robertson,et al. Caspase-9 Activation by the Apoptosome Is Not Required for Fas-mediated Apoptosis in Type II Jurkat Cells* , 2009, The Journal of Biological Chemistry.
[39] G. Cohen,et al. Proteasome-mediated Degradation of Smac during Apoptosis: XIAP Promotes Smac Ubiquitination in Vitro * , 2002, The Journal of Biological Chemistry.
[40] D. Lauffenburger,et al. Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.
[41] A. Letai,et al. Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.
[42] M. Diaz,et al. Surviving apoptosis: a possible mechanism of benzene-induced leukemia. , 2005, Chemico-biological interactions.
[43] H. Steller,et al. Regulation of apoptosis by XIAP ubiquitin-ligase activity. , 2008, Genes & development.
[44] Christoph Borner,et al. XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.
[45] D. Lauffenburger,et al. Direct Lyapunov exponent analysis enables parametric study of transient signalling governing cell behaviour. , 2006, Systems biology.
[46] P. Chaney,et al. SURVIVING , 1976, Nursing.
[47] C. Belka,et al. Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies , 2005, Oncogene.
[48] M. Rehm,et al. Dynamics of outer mitochondrial membrane permeabilization during apoptosis , 2009, Cell Death and Differentiation.
[49] R. Fisher. XV.—The Correlation between Relatives on the Supposition of Mendelian Inheritance. , 1919, Transactions of the Royal Society of Edinburgh.
[50] D. Lauffenburger,et al. A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines*S , 2005, Molecular & Cellular Proteomics.
[51] John Calvin Reed,et al. X-linked Inhibitor of Apoptosis Protein (XIAP) Inhibits Caspase-3 and -7 in Distinct Modes* , 2001, The Journal of Biological Chemistry.
[52] Mark H Ellisman,et al. Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the p75 Subunit of Complex I of the Electron Transport Chain , 2004, Cell.
[53] A. Vaughan,et al. Surviving apoptosis , 2004, Apoptosis.
[54] George Haller,et al. Optimal pollution mitigation in Monterey Bay based on coastal radar data and nonlinear dynamics. , 2007, Environmental science & technology.
[55] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.